Spatial/molecular heterogeneity and treatment response in HER2+ early breast cancer: Translational analyses from the DAPHNe trial
Emily Chen, Ilana Miriam Schlam, Kaoru Shimada, Tianyu Li, Esther Ritah Ogayo, Ashka Patel, Janae Davis, Jia‐Ren Lin, Austin Schultz, Madeline G Townsend, Kelly F Zheng, Carlos Wagner S Wanderley, Ricardo Pastorello, Felicia New, Evelyn Metzger, , Adrienne Gropper Waks
The paper analyzes HER2+ breast cancer using multi-platform data to identify molecular predictors of response to neoadjuvant therapy and highlights intra-tumoral heterogeneity and immune exclusion mechanisms.
bioRxiv · Sep 18, 2026 · PreprintCancer Biology